SILVESTRI, Carmela
 Distribuzione geografica
Continente #
NA - Nord America 1.773
EU - Europa 882
AS - Asia 327
AF - Africa 34
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.020
Nazione #
US - Stati Uniti d'America 1.771
UA - Ucraina 230
IE - Irlanda 120
TR - Turchia 120
SE - Svezia 115
IT - Italia 109
DE - Germania 95
DK - Danimarca 86
SG - Singapore 80
CN - Cina 72
FI - Finlandia 50
KR - Corea 47
FR - Francia 45
CI - Costa d'Avorio 33
GB - Regno Unito 13
RO - Romania 6
IN - India 4
NL - Olanda 4
CA - Canada 2
HK - Hong Kong 2
RS - Serbia 2
AL - Albania 1
AR - Argentina 1
CL - Cile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EU - Europa 1
IS - Islanda 1
LV - Lettonia 1
MA - Marocco 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
VN - Vietnam 1
Totale 3.020
Città #
Jacksonville 228
Chandler 224
Fairfield 208
Dublin 120
Wilmington 107
Ashburn 100
Boardman 99
Woodbridge 91
Houston 80
Cambridge 76
Seattle 69
New York 50
Lawrence 46
Princeton 46
San Mateo 44
Ann Arbor 35
Turin 35
Abidjan 33
Singapore 33
San Diego 17
Des Moines 12
Beijing 10
Buffalo 7
Izmir 7
Norwalk 7
Porto 7
Centro 6
Helsinki 5
Los Angeles 5
Dallas 4
London 4
Pune 4
Shanghai 4
Wuhan 4
Wuxi 4
Guangzhou 3
Kilburn 3
North Bergen 3
San Jose 3
Amsterdam 2
Belgrade 2
Campobasso 2
Clifton 2
Hong Kong 2
Longyan 2
Macerata 2
Pesaro 2
Toronto 2
Acton 1
Auckland 1
Berlin 1
Buenos Aires 1
Dalian 1
East Los Angeles 1
Fuzhou 1
Hangzhou 1
Hanover 1
Hengyang 1
Hounslow 1
Jiaxing 1
Kunshan 1
La Canada Flintridge 1
Lisbon 1
Nanjing 1
Nashville 1
Nicosia 1
Olomouc 1
Ozzano Monferrato 1
Prescot 1
Reykjavik 1
Riga 1
Santa Clara 1
Seoul 1
Serra 1
St. Petersburg 1
Tallinn 1
Tiantai Chengguanzhen 1
Tirana 1
Yeongdeungpo-gu 1
Yiwu 1
Zibo 1
Totale 1.894
Nome #
In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria. 94
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 82
In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. 82
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 81
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 81
Daptomycin and Rifampin Alone and in Combination Prevent Vascular Graft Biofilm Formation and Emergence of Antibiotic Resistance in a Subcutaneous Rat Pouch Model of Staphylococcal Infection. 79
Urinary catheters and biofilm formation 79
In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 78
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 78
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 76
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 74
In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 73
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. 73
Lipopeptide Laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis. 73
Vitamin E supplementation in old mice induces antimicrobial activity and improves the efficacy of daptomycin in an animal model of wounds infected with methicillin resistant Staphylococcus aureus. 71
In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. 71
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. 71
Quorum Sensing Inhibitor FS3-coated Vascular Graft Enhances Daptomycin Efficacy in a Rat Model of Staphylococcal Biofilm Infection. 71
In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. 70
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 70
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 70
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 69
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 68
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 67
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 66
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. 66
In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. 63
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 63
In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. 62
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 62
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 62
In vitro activities of tachyplesin III against Pseudomonas aeruginosa. 61
Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. 61
Vitamin E improves the in vivo efficacy of tigecycline and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus. 61
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 61
In vitro and in vivo effects of sub-MICs of pexiganan and imipenem on Pseudomonas aeruginosa adhesion and biofilm development. 61
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 58
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 57
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation 57
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 56
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 54
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 52
The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock 52
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. 49
Prevalence of intestinal parasites among individuals with allergic skin diseases. 46
Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis. 42
Totale 3.073
Categoria #
all - tutte 16.578
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.578


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020180 0 0 0 0 0 1 46 1 48 2 2 80
2020/2021791 53 77 99 11 74 64 96 62 76 64 82 33
2021/2022365 34 76 2 3 4 37 22 14 21 62 17 73
2022/2023647 58 97 52 43 41 65 2 31 160 4 75 19
2023/2024326 66 8 19 56 62 63 5 5 0 2 3 37
2024/2025228 98 49 34 6 40 1 0 0 0 0 0 0
Totale 3.073